Inovio Pharmaceuticals, Inc. News (NASDAQ:INO)

DateTimeSource
Headline
07/19/201710:10PMGLOBEInovio Announces Pricing of Public Offering of Common Stock
PLYMOUTH MEETING, Pa., July 19, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced the pricing of an underwritten public offering of 12,500,000 shares of its common stock, offered at a price to the public of $6.00 per share.  The gross proceeds to Inovio from the offering are expected to... More...>>
07/18/20174:01PMGLOBEInovio Announces Proposed Public Offering of Common Stock
PLYMOUTH MEETING, Pa., July 18, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it intends to offer and sell $75.0 million of shares of its common stock in an underwritten public offering.  Inovio expects to grant the underwriters an option to purchase up to an additional $11.25... More...>>
07/06/20178:00AMGLOBEInovio’s DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation
PLYMOUTH MEETING, Pa., July 06, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based monoclonal antibody product for flu produced broadly cross-reactive antibodies that provided complete protection from a lethal challenge with multiple viruses from both influenza A and B types... More...>>
06/28/20178:00AMGLOBEInovio Announces Leadership Appointments
PLYMOUTH MEETING, Pa., June 28, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced leadership appointments to support its growth and expanding strategic and operational initiatives. Inovio promoted Dr. Keiko Simon to Vice President, Alliance and Program Management and Jeffrey C. Richardson... More...>>
06/19/20178:00AMGLOBEInovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention
PLYMOUTH MEETING, Pa., June 19, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, President & CEO, will participate on a panel, titled “Platform Technologies: The Key to Responding to Emerging Infectious Diseases,” at the 2017 BIO International Conference... More...>>
06/15/20178:00AMGLOBEInovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Ef...
PLYMOUTH MEETING, Pa., June 15, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has completed enrollment of its phase 1 clinical trial in Puerto Rico evaluating its Zika vaccine, GLS-5700. Inovio is developing this vaccine with GeneOne Life Science, Inc. (KSE:011000) and academic... More...>>
06/08/20176:00AMGLOBEInovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer 
PLYMOUTH MEETING, Pa., June 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that it has commenced its phase 3 clinical program to evaluate the efficacy of Inovio’s DNA-based immunotherapy, VGX-3100, to treat cervical dysplasia caused by human papillomavirus (HPV). Inovio’s study... More...>>
06/07/20178:00AMGLOBEInovio Zika Vaccine Prevents Persistence of Virus and Damage in Male Reproductive Tract in Pre-Clinical Study
PLYMOUTH MEETING, Pa., June 07, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced its DNA-based Zika vaccine (GLS-5700) protected against Zika virus-induced damage to testes and sperm, and prevented persistence of the virus in the reproductive tract of all vaccinated male mice challenged... More...>>
06/01/20178:00AMGLOBEInovio Announces Clinical Trial Collaboration to Evaluate a Novel T-cell Immunotherapy in Combination with a PD-L1 Checkpoint...
PLYMOUTH MEETING, Pa., June 01, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced a clinical collaboration with Genentech, a member of the Roche Group, for advanced bladder cancer. The phase 1b/2 immuno-oncology trial will evaluate Genentech’s atezolizumab (TECENTRIQ®) in combination... More...>>
05/24/20178:00AMGLOBEInovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study
PLYMOUTH MEETING, Pa., May 24, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine. The vaccine candidate, PENNVAX-GP... More...>>
05/10/20178:00AMGLOBEInovio Provides Update on MedImmune Launch of Combination Trial for HPV-associated Head & Neck Cancer
PLYMOUTH MEETING, Pa., May 10, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced MedImmune, AstraZeneca’s global biologics research and development arm, will start a new clinical trial investigating the combination of MEDI0457, an immunotherapy designed to generate antigen specific killer... More...>>
05/08/20177:30AMPRNUSRegeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
Regeneron and Inovio Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy Phase 1b/2a clinical trial will combine Regeneron's PD-1 inhibitor REGN2810 and Inovio's T cell activator INO-5401 and immune activator INO-9012 in brain cancer PR Newswire TARRYTOWN, N.Y. and PLYMOUTH MEETING, Pa... More...>>
05/08/20177:30AMGLOBEInovio & Regeneron Enter Immuno-Oncology Clinical Study Agreement for Glioblastoma Combination Therapy
PLYMOUTH MEETING, Pa. and TARRYTOWN, N.Y., May 08, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced a clinical study agreement for a phase 1b/2a immuno-oncology trial. The study will be conducted by Inovio in patients with newly diagnosed... More...>>
05/02/20178:00AMGLOBEInovio Pharmaceuticals to Participate in Bank of America Merrill Lynch 2017 Healthcare Conference
PLYMOUTH MEETING, Pa., May 02, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will participate in the Bank of America Merrill Lynch 2017 Healthcare Conference May 16-18th, 2017 in Las Vegas, NV. Dr. J. Joseph Kim, President and CEO of Inovio, will host one-on-one meetings with... More...>>
04/26/20178:00AMGLOBEInovio Pharmaceuticals to Report First Quarter 2017 Financial Results May 10, 2017
PLYMOUTH MEETING, Pa., April 26, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 first quarter financial results on Wednesday, May 10, 2017 at 4:30 p.m. ET. A live and archived version of the audio presentation will... More...>>
04/24/20178:00AMGLOBEInovio Initiates Phase 2 Efficacy Trial with VGX-3100 For HPV-Related Vulvar Pre-Cancers
New study expands VGX-3100 program for evaluating therapeutic applications in HPV-related pre-cancers with high medical need VGX-3100 previously demonstrated efficacy in regressing HPV-related cervical pre-cancer PLYMOUTH MEETING, Pa., April 24, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO... More...>>
04/11/20179:00AMGLOBEInovio Ebola Vaccine Demonstrates Robust Immune Responses with Favorable Safety Profile in Expanded Clinical Trial
PLYMOUTH MEETING, Pa., April 11, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today preliminary results from the expanded stage of its phase I study, EBOV-001. The expanded study examined different regimens of its Ebola DNA vaccine INO-4201 using intradermal (skin) administration. The results... More...>>
03/30/20178:00AMGLOBEInovio and Collaborators Receive NIH Grant to Evaluate HIV Immunotherapy PENNVAX®-GP’s Ability to Induce Remission of HI...
PLYMOUTH MEETING, Pa., March 30, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its academic and industry collaborators received a multi-year $6.95 million grant from the NIH’s National Institute of Allergy and Infectious Diseases to develop a single or combination therapy using... More...>>
03/21/20178:00AMGLOBEGeorge Bickerstaff Elected to Inovio’s Board of Directors
PLYMOUTH MEETING, Pa., March 21, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today the election of George Bickerstaff to its Board of Directors.  Mr. Bickerstaff is an internationally recognized expert in finance, healthcare and information technology.  He has served Novartis... More...>>
03/15/20174:05PMGLOBEInovio Pharmaceuticals Reports 2016 Fourth Quarter and Year End Financial Results
PLYMOUTH MEETING, Pa., March 15, 2017 (GLOBE NEWSWIRE) -- Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2016. Total revenue was $8.5 million and $35.4 million for the quarter and year ended December 31, 2016, as compared to $5.9 million and... More...>>
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:31 V:us D:20170723 16:42:59